-
Derizhi: The first AI-aided design drug officially submitted an IND application to the FDA
Time of Update: 2023-01-05
On November 21, 2022, MindRank has formally submitted its self-developed potential "Best" to the US Food and Drug Administration (FDA) after completing its pre-IND communication meeting with the FDA in Class "Application for a new drug (IND) for type 2 diabetes mellitus and weight loss indication for non-competitive oral glucagon-like peptide 1 (GLP-1) receptor small molecule agonist MDR-001 was accepted.
-
Under the patent crisis of stone medicine Enbipu, it rose by 10%, AZ Andatang increased by 60% year-on-year, multinational pharmaceutical companies have recovered, and the top 10 varieties of in-hospital sales in 2022Q3 are here!
Time of Update: 2023-01-05
In the third quarter of 2022, China's hospital pharmaceutical market has recovered, but the development trend difference between local pharmaceutical companies and multinational pharmaceutical compani
-
China's clinical extraordinary decade | the development of clinical trials in China, leading the transformation of "global innovation" R&D!
Time of Update: 2023-01-05
Source: 2021 Drug Evaluation ReportThanks to the drug review reform that began in 2015 and a series of regulatory innovation measures have been introduced one after another, China's clinical trial and research level has changed from "following the run" in the third echelon in the past to "running alongside" in the second echelon now, facing the future and ranking among the first echelon "leading", crossing the threshold of standardization, standardization and internationalization.
-
Discussion on the positioning of rare disease catalogue and the improvement of drug innovation and accessibility
Time of Update: 2023-01-05
com Review proofreader: Zhang Zhijuan, Liu Fapeng Review proofreader: Zhang Zhijuan, Liu Fapeng In the face of the current problems such as import dependence of rare disease drugs, payment dilemma, and obstruction of access to medical institutions, it is necessary to form a "three-drug linkage" from the perspectives of medicine, medical insurance and medical treatment to promote the development of innovative rare disease industries.
-
First! FDA approves gene therapy for adult hemophilia
Time of Update: 2023-01-05
(FIX)Today's approved Hemgenix uses AAV5 vectors to deliver coagulation factor IX Transgenic of the Padua variant, which is 5-8 times more active than ordinary coagulation factor IX, can complete normal coagulation function at lower expression levels.
-
6 billion! The U.S. interest in another domestically produced PD-1 was sold
Time of Update: 2023-01-05
The maximum total transaction amount is about 6 billion RMBSlightly different from the common drug authorization transaction, this transaction sets up a VAM repurchase clause:After the third anniversary of Fosun Pharma's first commercial sale of slilumab, Henlius has the right to repurchase the relevant license rights for a consideration of three times the sales amount in the past one year, with a minimum of US$250 million.
-
Outbreak of rare disease drugs: In the past two years, 14 have been included in medical insurance and 13 have been approved for marketing
Time of Update: 2023-01-05
On June 10, 2020, the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China announced that the new drug application for the SMN2 gene splicing regulator risdiplam oral solution powder proposed to treat spinal muscular atrophy will be included in the priority review.
-
51 varieties are coming! 600 million market reshuffle, stone medicine, Luo Xin... Successfully break through, the country of biological medicine is approaching step by step?
Time of Update: 2023-01-05
On November 16, the results of the proposed selection of drugs in Hebei Province, which lasted for half a month, were officially announced, with a total of 51 varieties (98 drugs) to be selected, involving 74 manufacturers, including the exclusive anticancer drug elemi injection of CSPC Pharmaceutical Group, rabeprazole sodium for injection for non-medical gastric ulcer treatment drug of Shandong Luoxin Pharmaceutical, and oxacillin sodium for injection of star antibacterial drug of Beite Pharmaceutical.
-
Local ADC inventory: HER2, TROP2 are the most crowded, Hengrui, CSPC, Kelun, East China Medicine and other in-depth layout!
Time of Update: 2023-01-05
HER2 and TROP2 are the most crowdedHER2 and TROP2 are the most crowdedTarget clustering is a common phenomenon of global research and development, and this phenomenon is even more so in domestic ADC new drugs, according to statistics, 22 ADC drugs targeting the "number one target" HER2 have been announced in China, accounting for 26% of all products.
-
TCR-T therapy heats up, see how domestic and foreign cutting-edge enterprises break the TCR-T dilemma
Time of Update: 2023-01-05
The company's innovative technology platform fuses TCR targeting tumor antigens with immune effector domains that bind to CD3 receptors on the surface of T cells, which allows TCR to recognize intracellular cancer antigens with high affinity, which is expected to break through the limitations of existing antibody drugs and increase the number of identifiable targets from 10% to 90% "cold tumors" ImmunoScape ImmunoScapeOn September 20, preclinical biotech company ImmunoScape announced the completion of a new $14 million funding round.
-
The stock price crashed by 70%! Will this Biotech go bankrupt?
Time of Update: 2023-01-05
Rubraca is the second PARP inhibitor to be marketed in the world, originally developed by Pfizer and later transferred to Clovis, and its only commercial product.
Rubraca is the second PARP inhibitor to be marketed in the world, originally developed by Pfizer and later transferred to Clovis, and its only commercial product.
-
K drug apocalypse: 13 innovative drugs give up medical insurance, still red flags flutter?
Time of Update: 2023-01-05
2022 is a special year for Merck's PD-1 pembrolizumab (known as "K drug"). In 2022Q1, K drug surpassed Humira, the first blockbuster drug for ten consecutive years, with sales reaching US$4. 809 billi
-
Has invested in innovative projects such as Ascentage and Zhenzhen, and won 5 new drugs, what kind of companies does this institution favor when investing?
Time of Update: 2023-01-05
Since the launch of the Science and Technology Innovation Board, the marketization of valuation has become more and more obvious, promoting new discoveries in the value of the biomedical industry, and also testing the insight of investment institutions into the future development of enterprises and their forward-looking judgment on corporate value.
-
$10 billion is just the threshold, the highest selling $23.8 billion! The prediction of the top 10 global best-selling drugs in 2023
Time of Update: 2023-01-01
Table 1 Top 10 global best-selling drugs forecast in 2023 Source: References, PharmacoIntelligence HeadlinesPD-1 market is hot:PD-1 market is hot:K drugs are at the top of the list, and O drugs are ranked upK drugs are at the top of the list, and O drugs are ranked upIn 2023, Keytruda is expected to replace Comirnaty as the new global drug king with nearly $24 billion.
-
Forbes' "30 under 30" list is out, what changes are these young talents expected to bring to the healthcare field?
Time of Update: 2023-01-01
Arise hopes to improve access to eating disorder treatment through virtual care pathways, community support, and moreOriginal: _mstmutation="1" _msthash="220780" _msttexthash="11953110"> Image source: Curi Bio's official websiteMr. Elliot Fisher is the co-founder of Curi Bio. Curi Bio aims to use stem cell technology to develop organ-on-a-chip models of human heart and muscle tissue to test new drugs, and has built an AI-based data analysis platform.
-
【First Offering】Huawei Hengyuan completed tens of millions of Pre-A+ round financing to accelerate the clinical application of the immunization exemption pipeline
Time of Update: 2023-01-01
Arterial New Medicine learned for the first time that recently, Huawei Hengyuan (Beijing) Biomedical Technology Co. , Ltd. (hereinafter referred to as "Huawei Hengyuan") completed tens of millions of
-
Hong Kong stocks added 1 more "B" 18A pharmaceutical company, 4 new drugs in three years landed, why did Zaiding move towards biopharma?
Time of Update: 2023-01-01
For example, he said, "Some of the innovation of new targets is done by small biotechs or research institutes, who have been deeply engaged in a certain track for many years and have rich experience, but in terms of drug development, it is something that pharmaceutical companies like Zai Lab are better at, and the cooperation between the two parties can greatly improve the efficiency and success rate.
-
Breaking new tracks? Big Pharma is targeting a $50 billion weight loss market
Time of Update: 2023-01-01
Big Pharma targets $50bn obesity drugs market as demand booms； Financial Times Last year, when Novo Nordisk launched the diet drug Wegovy, the company hired American rapper and actress Queen Ratifah Latifah) to launch an awareness campaign aimed at removing the stigma that often surrounds obesity treatment.
-
Snapped up by three multinational giants, with a market value of more than 100 billion, what did this Biotech do right?
Time of Update: 2023-01-01
How critical is commercialization and capital capability for a Biotech to grow into a Biopharma?Reality tells us that it is enough for a small company to spend more than ten years, from being unknown, the CEO does not even have an office, can only work from home, into a market value of nearly 100 billion yuan, and is snapped up by multinational pharmaceutical giants.
-
The temptation to accelerate the review: four months shortened, worth $2.4 billion
Time of Update: 2023-01-01
However, pharmaceutical companies spending hundreds of millions of dollars to buy an acceleration coupon can also be regarded as a dangerous move and a sword that goes sideways.
